Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 β-lactamases at 2 hospitals in Taiwan

Lii Tzu Wu; Hwa Jen Wu; Jing Gung Chung; Yin Ching Chuang; Kuo Chen Cheng; Wen-Liang Yu

doi:10.1016/j.diagmicrobio.2005.09.005

Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 β-lactamases at 2 hospitals in Taiwan

Lii Tzu Wu, Hwa Jen Wu, Jing Gung Chung, Yin Ching Chuang, Kuo Chen Cheng, Wen-Liang Yu

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

From February to June 2003, 111 clinical isolates of Proteus mirabilis were mainly isolated from patients with respiratory or urinary tract infections hospitalized at 3 district hospitals (A, B, C) in central Taiwan. Among them, 34 (30.6%) strains, isolated within 2 hospitals (A and B), exhibited nonsusceptibility to cefotaxime with significant reduction of MIC (≥3 log₂ dilution) by the effect of clavulanic acid, which confirmed the phenotype of extended-spectrum β-lactamases (ESBLs). These ESBL producers were coresistant to gentamicin, isepamicin, and amikacin, but remained susceptible to ceftazidime (MIC, ≤0.5 μg/mL) and meropenem (MIC,

Original language	English
Pages (from-to)	89-94
Number of pages	6
Journal	Diagnostic Microbiology and Infectious Disease
Volume	54
Issue number	2
DOIs	https://doi.org/10.1016/j.diagmicrobio.2005.09.005
Publication status	Published - Feb 2006

Keywords

β-Lactamases
CTX-M
Proteus mirabilis

ASJC Scopus subject areas

Infectious Diseases
Immunology and Allergy
Virology
Parasitology
Microbiology
Immunology
Applied Microbiology and Biotechnology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.diagmicrobio.2005.09.005

Cite this

@article{ca1022d8d72341cc812c5f9e2444c2ba,

title = "Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 β-lactamases at 2 hospitals in Taiwan",

abstract = "From February to June 2003, 111 clinical isolates of Proteus mirabilis were mainly isolated from patients with respiratory or urinary tract infections hospitalized at 3 district hospitals (A, B, C) in central Taiwan. Among them, 34 (30.6%) strains, isolated within 2 hospitals (A and B), exhibited nonsusceptibility to cefotaxime with significant reduction of MIC (≥3 log2 dilution) by the effect of clavulanic acid, which confirmed the phenotype of extended-spectrum β-lactamases (ESBLs). These ESBL producers were coresistant to gentamicin, isepamicin, and amikacin, but remained susceptible to ceftazidime (MIC, ≤0.5 μg/mL) and meropenem (MIC, ",

keywords = "β-Lactamases, CTX-M, Proteus mirabilis",

author = "Wu, {Lii Tzu} and Wu, {Hwa Jen} and Chung, {Jing Gung} and Chuang, {Yin Ching} and Cheng, {Kuo Chen} and Wen-Liang Yu",

year = "2006",

month = feb,

doi = "10.1016/j.diagmicrobio.2005.09.005",

language = "English",

volume = "54",

pages = "89--94",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 β-lactamases at 2 hospitals in Taiwan

AU - Wu, Lii Tzu

AU - Wu, Hwa Jen

AU - Chung, Jing Gung

AU - Chuang, Yin Ching

AU - Cheng, Kuo Chen

AU - Yu, Wen-Liang

PY - 2006/2

Y1 - 2006/2

N2 - From February to June 2003, 111 clinical isolates of Proteus mirabilis were mainly isolated from patients with respiratory or urinary tract infections hospitalized at 3 district hospitals (A, B, C) in central Taiwan. Among them, 34 (30.6%) strains, isolated within 2 hospitals (A and B), exhibited nonsusceptibility to cefotaxime with significant reduction of MIC (≥3 log2 dilution) by the effect of clavulanic acid, which confirmed the phenotype of extended-spectrum β-lactamases (ESBLs). These ESBL producers were coresistant to gentamicin, isepamicin, and amikacin, but remained susceptible to ceftazidime (MIC, ≤0.5 μg/mL) and meropenem (MIC,

AB - From February to June 2003, 111 clinical isolates of Proteus mirabilis were mainly isolated from patients with respiratory or urinary tract infections hospitalized at 3 district hospitals (A, B, C) in central Taiwan. Among them, 34 (30.6%) strains, isolated within 2 hospitals (A and B), exhibited nonsusceptibility to cefotaxime with significant reduction of MIC (≥3 log2 dilution) by the effect of clavulanic acid, which confirmed the phenotype of extended-spectrum β-lactamases (ESBLs). These ESBL producers were coresistant to gentamicin, isepamicin, and amikacin, but remained susceptible to ceftazidime (MIC, ≤0.5 μg/mL) and meropenem (MIC,

KW - β-Lactamases

KW - CTX-M

KW - Proteus mirabilis

UR - http://www.scopus.com/inward/record.url?scp=31744449484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31744449484&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2005.09.005

DO - 10.1016/j.diagmicrobio.2005.09.005

M3 - Article

C2 - 16406185

AN - SCOPUS:31744449484

SN - 0732-8893

VL - 54

SP - 89

EP - 94

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 2

ER -

Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 β-lactamases at 2 hospitals in Taiwan

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this